Header Logo

Connection

CATHERINE HEALY to Adult

Back to Details
This is a "connection" page, showing publications CATHERINE HEALY has written about Adult.
CATHERINE HEALY
Connection Strength
0.537
Adult
  1. mRNA vaccines against respiratory viruses. Curr Opin Infect Dis. 2023 10 01; 36(5):385-393.
    View in: PubMed
    Score: 0.048
  2. Kinetics of maternal pertussis-specific antibodies in infants of mothers vaccinated with tetanus, diphtheria and acellular pertussis (Tdap) during pregnancy. Vaccine. 2020 08 18; 38(37):5955-5961.
    View in: PubMed
    Score: 0.039
  3. Association Between Third-Trimester Tdap Immunization and Neonatal Pertussis Antibody Concentration. JAMA. 2018 10 09; 320(14):1464-1470.
    View in: PubMed
    Score: 0.034
  4. Knowledge and attitiudes of pregnant women and their providers towards recommendations for immunization during pregnancy. Vaccine. 2015 Oct 05; 33(41):5445-5451.
    View in: PubMed
    Score: 0.028
  5. Tetanus and diphtheria toxoids and acellular pertussis vaccine uptake during pregnancy in a metropolitan tertiary care center. Vaccine. 2015 Sep 11; 33(38):4983-7.
    View in: PubMed
    Score: 0.028
  6. Acceptability of immunization in adult contacts of infants: possibility of expanding platforms to increase adult vaccine uptake. Vaccine. 2014 May 07; 32(22):2540-5.
    View in: PubMed
    Score: 0.025
  7. Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial. J Infect Dis. 2023 12 20; 228(12):1662-1666.
    View in: PubMed
    Score: 0.025
  8. Parent and provider perspectives on immunization: are providers overestimating parental concerns? Vaccine. 2014 Jan 23; 32(5):579-84.
    View in: PubMed
    Score: 0.025
  9. Knowledge and attitudes of postpartum women toward immunization during pregnancy and the peripartum period. Hum Vaccin Immunother. 2013 Sep; 9(9):1926-31.
    View in: PubMed
    Score: 0.024
  10. Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants. Clin Infect Dis. 2013 Feb; 56(4):539-44.
    View in: PubMed
    Score: 0.023
  11. How to communicate with vaccine-hesitant parents. Pediatrics. 2011 May; 127 Suppl 1:S127-33.
    View in: PubMed
    Score: 0.021
  12. Implementation of cocooning against pertussis in a high-risk population. Clin Infect Dis. 2011 Jan 15; 52(2):157-62.
    View in: PubMed
    Score: 0.020
  13. Pertussis immunization in a high-risk postpartum population. Vaccine. 2009 Sep 18; 27(41):5599-602.
    View in: PubMed
    Score: 0.018
  14. The cocoon strategy. Tex Med. 2008 Aug; 104(8):3.
    View in: PubMed
    Score: 0.017
  15. Pertussis serostatus among neonates born to Hispanic women. Clin Infect Dis. 2006 May 15; 42(10):1439-42.
    View in: PubMed
    Score: 0.014
  16. Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data: A Secondary Cross-Protocol Analysis of 5 Randomized Clinical Trials. JAMA Netw Open. 2025 05 01; 8(5):e2512763.
    View in: PubMed
    Score: 0.014
  17. COVID-19 Vaccine Hesitancy in Caregivers of Hospitalized Children From 2020 Through 2023. Hosp Pediatr. 2024 09 01; 14(9):701-713.
    View in: PubMed
    Score: 0.013
  18. Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis. 2004 Jul 15; 190(2):335-40.
    View in: PubMed
    Score: 0.013
  19. SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized Trials. JAMA Netw Open. 2024 05 01; 7(5):e2412835.
    View in: PubMed
    Score: 0.013
  20. Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials. JAMA Netw Open. 2023 07 03; 6(7):e2323349.
    View in: PubMed
    Score: 0.012
  21. Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age. N Engl J Med. 2022 11 03; 387(18):1673-1687.
    View in: PubMed
    Score: 0.011
  22. Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age. N Engl J Med. 2022 05 26; 386(21):2011-2023.
    View in: PubMed
    Score: 0.011
  23. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. N Engl J Med. 2022 Feb 10; 386(6):531-543.
    View in: PubMed
    Score: 0.011
  24. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med. 2021 Nov 04; 385(19):1774-1785.
    View in: PubMed
    Score: 0.011
  25. Outcome of infants born to hepatitis C infected women. Ir J Med Sci. 2001 Apr-Jun; 170(2):103-6; discussion 92-3.
    View in: PubMed
    Score: 0.010
  26. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 02 04; 384(5):403-416.
    View in: PubMed
    Score: 0.010
  27. Hepatitis C infection in an Irish antenatal population. Ir J Med Sci. 2000 Jul-Sep; 169(3):180-2.
    View in: PubMed
    Score: 0.010
  28. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA. 2014 May 07; 311(17):1760-9.
    View in: PubMed
    Score: 0.006
  29. Genomic polymorphic profiles in an Irish population with meningococcaemia: is it possible to predict severity and outcome of disease? Genes Immun. 2003 Dec; 4(8):533-40.
    View in: PubMed
    Score: 0.003
  30. The efficacy and tolerability of combination antiretroviral therapy in pregnancy: infant and maternal outcome. Int J STD AIDS. 2000 Apr; 11(4):220-3.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.